Entest Biomedical, Inc. Chairman & CEO Addressed Shareholders on Its New Company Blog Site Regarding COPD and Immunotherapeutic Cancer Vaccine

SAN DIEGO, CA--(Marketwire - March 11, 2010) - Entest BioMedical, Inc. (OTCBB: ENTB) announced today its CEO David Koos addressed the Company's shareholders and other interested parties on its new blog site. Topics covered in the interview included progress in the Stem Cell / Photoceutical treatment for COPD, immunotherapeutic cancer vaccine, potential grant funding and anticipated revenue sources for the Company. This interview may be heard on the Company's blog site, www.entestbioblog.com/live.

Entest Chairman & CEO David Koos stated, "The Company intends to hold live interviews on its blog site to clarify and update shareholders on progress being made by the Company. Also, there will be an opportunity for open forum discussions on news items previously announced. It is the Company's intention to utilize this blog site to address future plans as they develop."

Future webcasts will be announced prior to taking place so those wishing to participate can logon and join the discussion. Should you miss any interviews, they will be recorded and available on demand later.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB) is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). ENT - 576™ is a proprietary laser device currently under development by Entest. The Company has filed 3 patent applications relating to the treatment of COPD. Entest Biomedical, Inc. is a majority owned subsidiary of Bio-Matrix Scientific Group Inc. (OTCBB: BMSN). Recently Entest published in the peer reviewed literature its platform technology, which is available at http://www.translational-medicine.com/content/pdf/1479-5876-8-16.pdf

About Bio-Matrix Scientific Group:

Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a biotechnology company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories. David Koos serves as Chairman & CEO concurrently for BMSN and ENTB.

Forward-looking statements:

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Follow the Company's progress on Twitter:
http://twitter.com/Entest_BioMed